467 related articles for article (PubMed ID: 23210739)
1. Association of MDM2 and p53 polymorphisms with the advancement of cervical carcinoma.
Singhal P; Hussain S; Thakur N; Batra S; Salhan S; Bhambani S; Bharadwaj M
DNA Cell Biol; 2013 Jan; 32(1):19-27. PubMed ID: 23210739
[TBL] [Abstract][Full Text] [Related]
2. [Association of murine double minute 2 and P53 polymorphisms with breast cancer susceptibility].
Wang ML; Xu YX; Qian J; Wang FH
Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Feb; 47(2):124-8. PubMed ID: 23719102
[TBL] [Abstract][Full Text] [Related]
3. TP53, MDM2, NQO1, and susceptibility to cervical cancer.
Hu X; Zhang Z; Ma D; Huettner PC; Massad LS; Nguyen L; Borecki I; Rader JS
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):755-61. PubMed ID: 20200430
[TBL] [Abstract][Full Text] [Related]
4. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
5. Lack of evidence that proline homozygosity at codon 72 of p53 and rare arginine allele at codon 31 of p21, jointly mediate cervical cancer susceptibility among Indian women.
Bhattacharya P; Sengupta S
Gynecol Oncol; 2005 Oct; 99(1):176-82. PubMed ID: 16054204
[TBL] [Abstract][Full Text] [Related]
6. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
7. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
[TBL] [Abstract][Full Text] [Related]
8. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
9. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
[TBL] [Abstract][Full Text] [Related]
10. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.
Yoneda T; Kuboyama A; Kato K; Ohgami T; Okamoto K; Saito T; Wake N
Oncol Rep; 2013 Jul; 30(1):25-34. PubMed ID: 23624782
[TBL] [Abstract][Full Text] [Related]
11. TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study.
Abderrahmane R; Louhibi L; Moghtit FZ; Boubekeur A; Benseddik K; Boudjema A; Benrrahal F; Aberkane M; Fodil M; Saidi-Mehtar N
Pathol Oncol Res; 2015 Jul; 21(3):629-35. PubMed ID: 25537146
[TBL] [Abstract][Full Text] [Related]
12. Association of rheumatoid arthritis with Mdm2 SNP309 and genetic evidence for an allele-specific interaction between MDM2 and p53 P72R variants: a case control study.
Assmann G; Voswinkel J; Mueller M; Bittenbring J; Koenig J; Menzel A; Pfreundschuh M; Roemer K; Melchers I
Clin Exp Rheumatol; 2009; 27(4):615-9. PubMed ID: 19772793
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.
Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D
Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156
[TBL] [Abstract][Full Text] [Related]
14. Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck.
Yu H; Huang YJ; Liu Z; Wang LE; Li G; Sturgis EM; Johnson DG; Wei Q
Mol Carcinog; 2011 Sep; 50(9):697-706. PubMed ID: 21656578
[TBL] [Abstract][Full Text] [Related]
15. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer.
Lind H; Zienolddiny S; Ekstrøm PO; Skaug V; Haugen A
Int J Cancer; 2006 Aug; 119(3):718-21. PubMed ID: 16496380
[TBL] [Abstract][Full Text] [Related]
16. MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib.
Liu YC; Hsiao HH; Yang WC; Liu TC; Chang CS; Yang MY; Lin PM; Hsu JF; Lee CP; Lin SF
Mol Carcinog; 2014 Dec; 53(12):951-9. PubMed ID: 23818300
[TBL] [Abstract][Full Text] [Related]
17. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.
Wan Y; Wu W; Yin Z; Guan P; Zhou B
BMC Cancer; 2011 May; 11():208. PubMed ID: 21619694
[TBL] [Abstract][Full Text] [Related]
18. No association between SNP309 promoter polymorphism in the MDM2 and cervical cancer in a study from northeastern Brazil.
Meissner Rde V; Barbosa RN; Fernandes JV; Galvão TM; Galvão AF; Oliveira GH
Cancer Detect Prev; 2007; 31(5):371-4. PubMed ID: 18023538
[TBL] [Abstract][Full Text] [Related]
19. MDM2 SNP 309 human papillomavirus infection in cervical carcinogenesis.
Nunobiki O; Ueda M; Yamamoto M; Toji E; Sato N; Izuma S; Okamoto Y; Torii K; Noda S
Gynecol Oncol; 2010 Sep; 118(3):258-61. PubMed ID: 20538323
[TBL] [Abstract][Full Text] [Related]
20. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]